《Disney +》 迪士尼、Marvel、彼思、星球大戰…  CASIO VINTAGE × PAC-MAN 復古又俏皮的電子錶登場!   《Chicory:A Colorful Tale》中悅耳的音景   Jackie Robinson令《MLB The Show 21》收藏家封面意義非凡   置身於未來!官方宣布推出PS5全新VR控制器!   不容錯過!E3 2021「SQUARE ENIX PRESENTS SUMMER SHOWCASE」發表內容統整!   《Death’s Door》將於11月23日在PS4和PS5推出   IeSF公認的電競國際大賽日本代表決定戰「WSL 2021 Japan National Final」將於9月4日開幕!   「CAPCOM Pro Tour Online 2021」首場比賽於4月17日日本登場! 

BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development

商業

HEIDLEBERG, Germany, Jun 29, 2023 - (亞太商訊) - BioMed X, a German independent research institute, announces the start of its first research project in collaboration with Sanofi: "Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates" (VPE). The end goal of this research project is to develop a versatile computational platform that can predict the efficacy of first- or best-in-class drug candidates in virtual patient populations at unprecedented accuracy, thereby addressing one of the most critical bottlenecks of the pharmaceutical industry today: a 90% failure rate of new drug candidates during clinical development.

The new research team will be led by Dr. Douglas McCloskey, a scientist and entrepreneur jointly selected by the Sanofi and BioMed X Institute management for the group leader position. "Most drug candidates that fail during clinical development do so due to a lack of efficacy compared to the standard of care. Our mission is to develop a platform to test-drive drug development candidates in virtual patients to gate the best ones into the clinic," explained the newly-appointed group leader of team VPE. "To tackle this challenge, our team at BioMed X will push the frontier of in silico drug discovery and development using our AI expertise with coaching from our industry partners," added Dr. McCloskey.

Christian Tidona, Founder and Managing Director of the BioMed X Institute: "After two years of collaborating on AI-powered drug discovery and development projects with our strategic partner in Israel, AION Labs, we are now ready to start our first AI-based research team in Heidelberg, Germany, together with our new pharma partner, Sanofi."

The "Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates" (VPE) team joins eight other active research teams at the BioMed X Institute in Germany, and it is one of four new projects launched by BioMed X in 2023. To learn more about this new AI-based research group, visit the BioMed X Institute website at www.bio.mx.

About BioMed X

BioMed X is an independent research institute located on the campus of the University of Heidelberg in Germany, with a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
[email protected]
+49 6221 426 11 706

Copyright 2023 亞太商訊. All rights reserved. www.acnnewswire.com
ACN Newswire

隨機商業新聞

NordVPN